Pharmacokinetic and pharmacodynamic properties of meropenem
- PMID: 18713048
- DOI: 10.1086/590064
Pharmacokinetic and pharmacodynamic properties of meropenem
Abstract
Pharmacokinetic and pharmacodynamic profiles of antibiotics are important in determining effective dosing regimens. Although minimum inhibitory concentration (MIC) data reflect microbial susceptibility to an antibiotic, they do not provide dosing information. The integration of pharmacokinetic and microbiological data, however, can be used to design rational dosing strategies. Meropenem is a broad-spectrum beta-lactam antibiotic that penetrates most body fluids and tissues rapidly after intravenous administration. Meropenem undergoes primarily renal elimination; therefore, dosage adjustment is required for patients with renal impairment. Meropenem is indicated for the treatment of complicated skin and skin-structure infections, complicated intra-abdominal infections, and bacterial meningitis. Meropenem has time-dependent bactericidal activity; thus, the percentage of time that free-drug concentrations are higher than the MIC (%T>MIC) best characterizes the drug's pharmacodynamic profile (bactericidal target of approximately 40%T>MIC). Pharmacodynamic modeling can identify regimens with the greatest probability of attaining this target, and probabilities can be compared with clinical and microbiological responses in patients.
Similar articles
-
Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.J Clin Pharmacol. 2003 Oct;43(10):1116-23. doi: 10.1177/0091270003257225. J Clin Pharmacol. 2003. PMID: 14517194
-
Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.Ann Pharmacother. 2005 Jan;39(1):32-8. doi: 10.1345/aph.1E271. Epub 2004 Dec 14. Ann Pharmacother. 2005. PMID: 15598967
-
Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.Pharmacotherapy. 2008 Jun;28(6):691-8. doi: 10.1592/phco.28.6.691. Pharmacotherapy. 2008. PMID: 18503396
-
Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.Clin Infect Dis. 2008 Sep 15;47 Suppl 1:S41-51. doi: 10.1086/590065. Clin Infect Dis. 2008. PMID: 18713049 Review.
-
Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.Pharmacotherapy. 2006 Sep;26(9):1320-32. doi: 10.1592/phco.26.9.1320. Pharmacotherapy. 2006. PMID: 16945055 Review.
Cited by
-
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae.Infect Drug Resist. 2018 Sep 12;11:1461-1472. doi: 10.2147/IDR.S150447. eCollection 2018. Infect Drug Resist. 2018. PMID: 30254477 Free PMC article. Review.
-
Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review.Clin Pharmacokinet. 2022 May;61(5):593-617. doi: 10.1007/s40262-021-01102-1. Epub 2022 Feb 25. Clin Pharmacokinet. 2022. PMID: 35218003 Free PMC article. Review.
-
Impact of erythrocytes on bacterial growth and antimicrobial activity of selected antibiotics.Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):485-495. doi: 10.1007/s10096-018-03452-4. Epub 2019 Jan 28. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30687870 Free PMC article.
-
Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools.Antibiotics (Basel). 2022 Jun 2;11(6):758. doi: 10.3390/antibiotics11060758. Antibiotics (Basel). 2022. PMID: 35740164 Free PMC article.
-
Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29439978 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical